// App-Quantinova.ai

PB0072 : Apolipoprotein A-IV Is an Endogenous Inhibitor of Thrombosis: The Roles of Polymorphisms in the Risk of Cardiovascular Disease

Researchers

Presenter

  • S.-Y. Yu

Principal Investigators

  • D. MacKeigan

  • M. Neves

  • P. Chen

  • H. Ni

Medical Centers

  • St. Michael's Hosp, Toronto, ON, Canada

  • Xiangya Hospital Central South University, Changsha, China

  • Canadian Blood Services, Centre for Innovation, Edmonton, Canada

Locations

  • Canada

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Apolipoprotein A-4

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved